Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 3 Cancer Trials

Research area

Phase 3 Prostate Cancer trials

The prostate cancer studies listed here are all in Phase 3, including combined Phase 2/3. If you are wondering whether one may be a fit, Phase 3 Cancer Trials can help you find out.

Updated

Call (888) 306-7888
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Phase 3 prostate cancer studies in numbers

Phase 3 prostate cancer studies recruiting in the U.S.
46
states with a study site
51
studies that accept healthy volunteers
1

Source: ClinicalTrials.gov. Data processed .

Find Phase 3 prostate cancer studies by state

These states have the most studies recruiting right now.

Phase 3 prostate cancer studies recruiting now

As of November 18, 2026, 46 Phase 3 prostate cancer studies are recruiting participants in the United States, according to ClinicalTrials.gov. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry. This is what they have in common.

What they test

  • medications38
  • other approaches12
  • procedures12
  • radiation9
  • devices2

A study can test more than one.

Main purpose

  • treating a condition37
  • diagnosis5
  • how care is delivered1
  • prevention1

Phase

  • Phase 2/36
  • Phase 340

Who runs them

  • university, hospital or other26
  • industry20

Who they enroll

  • adults (18 to 64)46
  • older adults (65 and over)46

1 also accept healthy volunteers.

These counts come from each study's public record and change as studies open and close. Browse every location to see what is recruiting near you.

Source: ClinicalTrials.gov. Data processed . Each bar shows a count as a share of all 46 studies.

Recently updated Phase 3 prostate cancer studies

The 6 studies whose public records changed most recently, with some of the places each is recruiting. Select a study to read its full record on ClinicalTrials.gov.

  1. A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    BioNTech SE
    Recruiting in
    Albany, NY · Atlanta, GA · Aurora, CO · and 18 more U.S. locations
    Registry record
    NCT07365995 · updated
  2. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Recruiting in
    Aberdeen, WA · Alton, IL · Altoona, PA · and 201 more U.S. locations
    Registry record
    NCT04423211 · updated
  3. Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Aberdeen, SD · Aurora, CO · Austin, TX · and 28 more U.S. locations
    Registry record
    NCT06136624 · updated
  4. A Study of Changes to Prostate Procedures

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Memorial Sloan Kettering Cancer Center
    Recruiting in
    Basking Ridge, NJ · Commack, NY · Harrison, NY · and 4 more U.S. locations
    Registry record
    NCT06986083 · updated
  5. Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Alliance for Clinical Trials in Oncology
    Recruiting in
    Ames, IA · Anaconda, MT · Antigo, WI · and 167 more U.S. locations
    Registry record
    NCT06931340 · updated
  6. A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Janssen Research & Development, LLC
    Recruiting in
    Ann Arbor, MI · Aurora, CO · Bala-Cynwyd, PA · and 42 more U.S. locations
    Registry record
    NCT07164443 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in the United States on ClinicalTrials.gov.

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and some of the places it is recruiting) exactly as registered. Nothing in a record is reworded. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry.

Phase 3 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

What Phase 3 prostate cancer studies look at

Every prostate cancer study listed here is in Phase 3, and that includes combined Phase 2/3. Each one is built around a single, specific question. Your part in it follows from that question, so your role will differ between studies.

The product under study is always investigational. Its risks are not fully understood yet, and neither is how well it works. The study exists to learn both.

Who may be able to take part

No single set of rules covers every prostate cancer study. A study may look at your age, your health history and the medications you take now. It may also consider how the condition affects you. People without the condition can join certain studies too.

Deciding whether you fit is the study team's job, not yours. They confirm it when you come in for screening. Our guide to eligibility and screening explains the process.

What taking part usually involves

  1. A first conversation

    Nothing else happens until a coordinator has spoken with you. They describe the Phase 3 prostate cancer study in general terms. Your questions get answered at this point too.

  2. Informed consent

    You receive the full details of the Phase 3 study in writing. The study team includes the risks that are known. The choice to agree, or not, rests with you.

  3. Screening

    You answer health questions and have some tests. Together they reveal whether this Phase 3 cancer trial is a fit for you. Being screened does not always lead to joining the study.

  4. Study visits

    Joining means coming to scheduled visits. They let the team follow your health through the Phase 3 trial. Leaving the study is possible at any time.

Questions about Phase 3 prostate cancer studies

Do I need a diagnosis to join a study about prostate cancer?

The answer differs from one Phase 3 prostate cancer study to the next. A confirmed diagnosis is asked for in some. In others, you are assessed during screening. The study team lets you know which one applies to you.

Would I have to change the care I receive now?

It depends on the Phase 3 study. In some, your current prostate cancer care can continue. In others, it cannot. Please make no changes to your care by yourself. At the study, the doctor will look at your current care together with you. You are also free to raise it with your own doctor, ahead of any decision.

Is there a cost to take part?

As a rule, you are not charged for the study medication, the tests done for the study, or its visits. See our guide to costs.

Ask about Phase 3 prostate cancer studies

Give us a few details, and a coordinator gets in touch with you. Asking puts you under no obligation.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Independent information

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 306-7888

or send a short form

How should we reach you?

Call